Preparing your Shotlee experience
Aardvark Therapeutics is developing ARD-101, an oral therapeutic to suppress hunger in Prader-Willi Syndrome patients. An analyst estimates a $10 billion market for PWS treatments, with Aardvark also exploring applications for obesity.
Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a biopharmaceutical company in the clinical stage, focused on creating small-molecule therapeutics. These therapeutics are designed to reduce hunger in individuals with Prader-Willi Syndrome (PWS) and various metabolic diseases.
Their leading compound, ARD-101, is an oral medication currently undergoing Phase 3 clinical trials for hyperphagia related to PWS. PWS is a rare condition characterized by persistent, intense hunger. It may be useful to use health tracking apps like Shotlee to monitor the effect of this drug.
The first patient in Australia was dosed with ARD-101 in a Phase 3 HERO clinical trial, Aardvark Therapeutics announced on Wednesday.
Furthermore, clinical trial sites located in Canada and the United Kingdom have also received regulatory approval to begin enrollment.
William Blair has initiated coverage of Aardvark Therapeutics, giving the company an Outperform rating.
Due to robust enrollment within the U.S. and sustained advancement of the international clinical trial, topline data is still expected in the third quarter of 2026.
According to William Blair's estimations, the global total addressable market (TAM) for PWS is approximately $10 billion. Currently, there is only one approved treatment available.
Analyst Andy Hsieh suggests that this opportunity alone justifies the company's valuation framework.
Aardvark is also working on ARD-201, a planned combination of ARD-101 with a DPP-4 inhibitor, and running two distinct trials to address some limitations of existing GLP-1 therapies for treating obesity and related conditions.
The TAM for ARD-201 could reach at least $100 billion, potentially serving as an oral and more tolerable alternative to GLP-1RAs. Both maintenance and induction settings are being explored.
William Blair indicates a significant difference between the current market value of $304 million and the potential of the primary program, ARD-101.
Aardvark reported having $126.4 million in cash, cash equivalents, and short-term investments. This amount is projected to be sufficient to fund operations into 2027.
Aardvark Therapeutics shares were trading at $14.63, down 6.28%, at the time of publication on Friday.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from Benzinga
View Original Article
Following Novo Nordisk's price reduction for its Wegovy injection, generic drug manufacturers are reassessing their pricing strategies. The move comes amid increasing competition in the weight-loss drug market, with potential impacts on affordability and market share.
A new Optum Rx report identifies three drugs targeting chronic conditions that are under review by the FDA. The medications address significant cost drivers for payers, including weight management and chronic inflammatory conditions.
The U.S. government has successfully negotiated a 71% discount on Novo Nordisk's popular drugs Ozempic and Wegovy for Medicare beneficiaries. These price reductions, resulting from recent legislation, will be implemented in 2027, potentially saving millions of dollars.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨